Boston Scientific Reports $269M Loss in 3Q
17th Oct 2005, 12:32 GMT
Boston Scientific acknowledged it has lost ground to its only medical device rival in the lucrative market for drug-coated heart stents, reporting a $269 mln Q3 loss and slowing sales of a stent that it rode to big profits last year.
Latest news from Angiography/ Cardiac Cath News from StratCenter.com:
- Thinking Systems Releases Enhanced PET-CT Functions for Its ThinkingPACS
- Tallahassee Memorial Hospital at the Forefront in Treatment of Heart Attack Patients
- Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease